Glaucoma drug therapy continues to evolve with Rho kinase inhibitors that specifically target glaucomatous abnormalities such as trabecular meshwork outflow.
“Rho kinase inhibitors are specific for targeting glaucomatous abnormalities by targeting the trabecular outflow pathway, relaxing the trabecular meshwork, and increasing conventional outflow,” Dr. Ou said.
“They have novel mechanisms of action. The fixed-combination of netarsudil and latanoprost lowers IOP approximately by an additional 2 to 3 mm Hg compared with netarsudil alone. The side effects include conjunctival hyperemia, petechial hemorrhages, and corneal verticillata. There are no systemic side effects,” Dr. Ou concluded.
Editor’s Note: This article was written prior to the March 2019 approval of netarsudil and latanoprost ophthalmic solution 0.02%/0.005% (Rocklatan, Aerie Pharmaceuticals) and has since been updated to reflect the announcement.
Yvonne Ou, MD
E: [email protected]
Dr. Ou is a consultant and advisor to Merck & Co. Inc.